Understanding attitudes towards naloxone prescriptions for opioid overdose
A Survey of High Risk Patient and Caregiver Attitudes and Beliefs Regarding the Prescription of Intranasal Naloxone Spray for Opioid Overdose
M.D. Anderson Cancer Center · NCT04129138
This study looks at what patients and their caregivers think about getting naloxone prescriptions to help prevent opioid overdoses.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | M.D. Anderson Cancer Center (other) |
| Locations | 1 site (Houston, Texas) |
| Trial ID | NCT04129138 on ClinicalTrials.gov |
What this trial studies
This observational trial examines the attitudes and beliefs of high-risk patients and their caregivers regarding the prescription of intranasal naloxone spray for opioid overdose. The study aims to determine how many patients and caregivers perceive naloxone prescriptions as beneficial and to explore the characteristics that influence these perceptions. Participants will complete a survey that assesses their views on naloxone, which may help identify barriers to prescribing and inform educational efforts tailored to their needs.
Who should consider this trial
Good fit: Ideal candidates include high-risk patients who have been prescribed intranasal naloxone within the past year and their caregivers.
Not a fit: Patients experiencing emotional or psychosocial distress or with significant anxiety may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of patient and caregiver perspectives, leading to improved naloxone prescribing practices and potentially reducing opioid overdose deaths.
How similar studies have performed: While there is limited data on this specific approach, understanding patient and caregiver attitudes towards naloxone has shown promise in other studies focused on opioid overdose prevention.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients must have been prescribed intranasal naloxone in the past 1 year * Patients and caregivers must be able to understand, read, write, and speak English * Patients must have no clinical evidence of cognitive impairment, as determined by the palliative care provider (Memorial Delirium Assessment Scale score of \>= 7) * Patients must sign an informed consent * Caregivers may sign an informed consent if available during the visit * Caregivers may verbally consent over the phone if not present during the visit * Caregiver must be a friend, significant other or family member * Caregivers must have no evidence of cognitive impairment, as determined based on orientation questions pertaining to the date, day of the week, time, and place Exclusion Criteria: * PATIENT: Emotional or psychosocial distress as identified by the patient's palliative care * PATIENT: Participants with Edmonton Symptom Assessment System (ESAS) anxiety score of \> 6
Where this trial is running
Houston, Texas
- M D Anderson Cancer Center — Houston, Texas, United States (RECRUITING)
Study contacts
- Principal investigator: Jaya S Amaram-Davila, MD — M.D. Anderson Cancer Center
- Study coordinator: Jaya S. Amaram-Davila, MD
- Email: jsamaram@mdanderson.org
- Phone: (713) 792-6085
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Caregiver, Patient